1370001-96-9

Basic information

• Product Name: 4-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyriMidine
• Synonyms: 4-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyriMidine;(4-METHYLPYRIMIDIN-5-YL)BORONIC ACID PINACOL ESTER
• CAS NO: 1370001-96-9
• Molecular Formula: C11H17BN2O2
• Molecular Weight: 220.07588
• Mol File: 1370001-96-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 328.1±30.0 °C(Predicted)
• Appearance: /
• Density: 1.06±0.1 g/cm3(Predicted)
• PKA: 1.66±0.16(Predicted)
• CAS DataBase Reference: 4-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyriMidine(1370001-96-9)
• EPA Substance Registry System: 4-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyriMidine(1370001-96-9)

Safety Data

• Hazardous Substances Data: 1370001-96-9(Hazardous Substances Data)

Upstream product

• 1439-09-4 5-bromo-4-methylpyrimidine 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1609579-44-3 2-[5-(furo[3,2-c]pyridin-4-yloxy)-2-(4-methylpyrimidin-5-yl)phenyl]-2-methylpropanenitrile 
• 1609581-87-4 2-[5-hydroxy-2-(4-methylpyrimidin-5-yl)phenyl]-2-methylpropanenitrile 
• 1428879-92-8 7-(4-methylpyrimidin-5-yl)-3-phenylbenzo[d]isoxazole 

Relevant articles and documents

MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS

The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.

BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1

The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.